Pregnancy is a unique physiological state characterized by profound adaptations to support the developing fetus. While these changes are essential for a healthy pregnancy, they also predispose the mother to specific medical complications. Among the most significant of these are thromboembolic disorders, which remain a leading cause of maternal mortality and morbidity worldwide. The hemostatic system undergoes a complex rebalancing during gestation, creating a state of relative hypercoagulability.
Understanding the Physiological Basis of Hypercoagulability in Pregnancy
To comprehend why pregnant individuals are at an increased risk for thrombosis, it is crucial to first understand the physiological changes that occur within the hemostatic system. These changes are not random; they are an evolutionary adaptation designed to prevent catastrophic hemorrhage during childbirth and facilitate uterine involution postpartum. This “Virchow’s Triad” of stasis, endothelial injury, and hypercoagulability is amplified during pregnancy.
- Increased Coagulation Factors: The concentrations of several key coagulation factors rise significantly during gestation. Fibrinogen (Factor I) levels can double by the third trimester. Factors VII, VIII, IX, X, and XII also demonstrate increased activity. This creates a robust potential for fibrin formation and clot development.
- Decreased Fibrinolysis: The body’s natural clot-dissolving system, known as fibrinolysis, is actively suppressed. Levels of Protein S (a natural anticoagulant) decrease, and the activity of Plasminogen Activator Inhibitor-1 (PAI-1) and Plasminogen Activator Inhibitor-2 (PAI-2) increase. This suppression prevents the breakdown of the fibrin matrix essential for the placental barrier but simultaneously impairs the body’s ability to dissolve unwanted clots.
- Mechanical Factors (Venous Stasis): As the uterus enlarges, it exerts direct pressure on the inferior vena cava and the pelvic veins. This compression impedes venous return from the lower extremities, leading to venous stasis. This effect is often most pronounced in the third trimester and is exacerbated by prolonged immobilization.
These three elements—increased procoagulants, decreased anticoagulants/fibrinolytic activity, and venous stasis—work in concert to create a physiological state that is highly conducive to thrombus formation, making pregnancy a significant hypercoagulable state.
Conducting a Thorough Risk Assessment
Not all pregnant individuals carry the same level of risk. A systematic risk assessment is the cornerstone of preventing adverse outcomes. This assessment should be performed at the first prenatal visit and re-evaluated as new risk factors emerge (e.g., hospitalization, surgical procedures).
Risk factors can be broadly categorized into inherited/acquired conditions and pregnancy-specific/labor-and-delivery-related factors.
Inherited and Acquired Thrombophilias:
- Factor V Leiden Mutation: The most common inherited thrombophilia, leading to activated Protein C resistance.
- Prothrombin G20210A Mutation: A mutation in the prothrombin gene leading to elevated prothrombin levels.
- Deficiencies of Natural Anticoagulants: Antithrombin III, Protein C, and Protein S deficiencies.
- Antiphospholipid Syndrome (APS): An autoimmune disorder characterized by antibodies that increase the risk of both arterial and venous thrombosis.
Other Medical and Personal History Factors:
- Personal History of VTE: A previous deep vein thrombosis (DVT) or pulmonary embolism (PE) is the single most significant risk factor for recurrence in pregnancy.
- Family History of VTE: A first-degree relative with a history of VTE, especially if associated with a known thrombophilia.
- Obesity (BMI > 30 kg/m²): Contributes to venous stasis and a pro-inflammatory state.
- Advanced Maternal Age (>35 years).
- Medical Comorbidities: Systemic lupus erythematosus, inflammatory bowel disease, nephrotic syndrome, sickle cell disease, heart disease, and malignancy.
Pregnancy-Specific and Obstetric Risk Factors:
- Multiparity: Carrying more than one fetus.
- Pre-eclampsia/Eclampsia: The associated endothelial dysfunction and coagulopathy increase thrombotic risk.
- Hyperemesis Gravidarum with Dehydration.
- Immobility: Prolonged bed rest or paralysis.
- Obstetric Hemorrhage: Massive hemorrhage can paradoxically lead to a hypercoagulable state (Disseminated Intravascular Coagulation – DIC).
- Surgical Procedures: Cesarean delivery, especially an emergency procedure.
- Assisted Reproductive Technology (ART): Ovulation induction and the underlying infertility may be associated with an increased risk.
Clinical tools, such as the Caprini Risk Assessment Model, are often adapted for use in obstetrics to systematically quantify this risk and guide prophylaxis decisions.
Recognizing the Clinical Presentation and Diagnostic Challenges
Timely diagnosis is critical but can be challenging, as the signs and symptoms of VTE often mimic normal pregnancy changes.
1. Deep Vein Thrombosis (DVT): DVT most commonly occurs in the left lower extremity due to anatomical compression of the left iliac vein by the right iliac artery. Classic signs include:
- Unilateral leg swelling, particularly below the knee.
- Pain, tenderness, or cramping in the calf.
- Increased warmth and erythema (redness) over the affected area.
- Palpable cord (a hardened, tender superficial vein).
However, mild unilateral swelling and aching are common in late pregnancy, making clinical diagnosis alone unreliable.
2. Pulmonary Embolism (PE): A PE occurs when a portion of a thrombus breaks off, travels through the venous system, and lodges in the pulmonary arteries. It is a life-threatening emergency. Symptoms can range from subtle to catastrophic:
- Sudden onset of shortness of breath (dyspnea) or rapid breathing (tachypnea).
- Chest pain, often sharp and pleuritic (worsens with deep inspiration).
- Cough, sometimes with hemoptysis (coughing up blood).
- Tachycardia (rapid heart rate).
- Syncope (fainting), hypotension, or signs of right heart strain.
Because dyspnea is a common complaint in late pregnancy, a high index of suspicion is necessary for any new or worsening respiratory symptoms.
Diagnostic Imaging:
- For Suspected DVT: The gold standard is a compression ultrasonography (CUS) of the lower extremities. It is non-invasive and highly accurate.
- For Suspected PE: The diagnostic algorithm is more complex due to radiation concerns with standard imaging. A Ventilation-Perfusion (V/Q) scan is often preferred over a CT Pulmonary Angiogram (CTPA) in pregnancy, as it generally delivers a lower radiation dose to the fetus. However, CTPA is also considered safe and may be necessary depending on clinical context and institutional protocols.
Implementing Evidence-Based Management and Treatment
Once a VTE is confirmed, immediate and effective treatment is essential to prevent morbidity and mortality.
Primary Treatment: Anticoagulation
The mainstay of treatment is anticoagulation therapy.
- Low-Molecular-Weight Heparin (LMWH): Enoxaparin and dalteparin are the agents of choice. LMWH does not cross the placenta and is therefore not teratogenic. It has a predictable dose response, a lower risk of heparin-induced thrombocytopenia (HIT) compared to unfractionated heparin (UFH), and does not require routine monitoring. Treatment is typically administered once or twice daily via subcutaneous injection.
- Unfractionated Heparin (UFH): This agent may be used in specific situations, such as severe renal insufficiency or if a rapid reversal is anticipated (e.g., planned delivery or high risk of bleeding). It requires intravenous administration and frequent monitoring (aPTT), making it less convenient than LMWH.
- Warfarin and DOACs: Vitamin K antagonists (e.g., warfarin) are teratogenic and are contraindicated in pregnancy. Direct Oral Anticoagulants (DOACs) like apixaban or rivaroxaban are also not recommended due to insufficient safety data and placental transfer.
Treatment for an acute VTE in pregnancy should continue for a minimum of three months and for the duration of pregnancy and at least 6 weeks postpartum, for a total minimum course of 3 months.
Distinguishing Between Prophylaxis and Therapeutic Dosing
The principles of managing thromboembolic disorders extend beyond treating an acute event to preventing one in the first place.
- Prophylaxis (Prevention): Prophylactic anticoagulation is indicated for individuals with a high-risk profile. This involves administering a lower dose of LMWH (e.g., enoxaparin 40 mg subcutaneously daily) to prevent clots from forming. The decision to initiate prophylaxis is based on the individual’s cumulative risk score from the assessment.
- Therapeutic Dosing (Treatment): This involves using higher, weight-based doses of LMWH (e.g., enoxaparin 1 mg/kg every 12 hours) to prevent the growth of an existing clot and allow the body’s natural fibrinolysis to dissolve it over time.
Planning for Labor, Delivery, and the Postpartum Period
The peripartum period is a time of extremely high thrombotic risk. Careful planning is required to manage anticoagulation safely.
Intrapartum Management:
- Discontinuation of Anticoagulation: For patients on prophylactic or therapeutic LMWH, the dose must be stopped in anticipation of labor or a scheduled cesarean section. The last dose of prophylactic LMWH should be given no less than 12 hours before neuraxial anesthesia (epidural/spinal) or surgical incision. For therapeutic-dose LMWH, this interval is 24 hours.
- Use of UFH: In rare cases where anticoagulation must be continued during the immediate peripartum period (e.g., a very high-risk patient with a recent acute VTE), an intravenous UFH infusion is used because its effects can be rapidly reversed with protamine sulfate.
Postpartum Management: The risk of VTE is highest in the first 6 weeks postpartum. All patients on therapeutic anticoagulation should have this therapy re-initiated postpartum.
- Timing: Anticoagulation can typically be restarted 4 to 6 hours after a vaginal delivery or 6 to 12 hours after a cesarean section, assuming hemostasis is achieved.
- Duration: As mentioned, treatment should continue for at least 6 weeks postpartum, for a total course of at least 3 months. Patients with a new diagnosis of VTE in pregnancy must complete a full therapeutic course.
- Breastfeeding: Both LMWH and warfarin are considered compatible with breastfeeding and are safe to use during the postpartum period.
Conclusion
Thromboembolic disorders in pregnancy represent a critical intersection of maternal physiology and pathology. A proactive, systematic approach is essential for mitigating risk and preventing adverse outcomes. This begins with a fundamental understanding of the hypercoagulable state of pregnancy, followed by a meticulous, individualized risk assessment. Prompt diagnosis using appropriate imaging modalities and evidence-based management with pregnancy-safe anticoagulants (primarily LMWH) are the pillars of treatment. Finally, a carefully coordinated plan for the peripartum period, with clear instructions on the timing of anticoagulation discontinuation and re-initiation, ensures that both the mother and the newborn are protected from this significant threat to maternal health. Through education and adherence to established guidelines, healthcare professionals can significantly reduce the morbidity and mortality associated with thromboembolism in pregnancy.
References
American College of Obstetricians and Gynecologists. (2018). Thromboembolism in pregnancy (Practice Bulletin No. 196). Obstetrics & Gynecology, 132(1), e1-e17.
James, A. H., Jamison, M. G., Brancazio, L. R., & Myers, E. R. (2006). Venous thromboembolism during pregnancy and the postpartum period: Incidence, risk factors, and mortality. American Journal of Obstetrics and Gynecology, 194(5), 1311–1315. https://doi.org/10.1016/j.ajog.2005.11.008
Larson, L. A., & Connors, J. M. (2022). Thromboembolic disease in pregnancy. Hematology, 2022(1), 203–209. https://doi.org/10.1182/hematology.V2022.1.203
Pomp, E. R., Lenselink, A. M., Rosendaal, F. R., & Doggen, C. J. (2008). Pregnancy, the postpartum period and prothrombotic defects: Risk of venous thrombosis in the MEGA study. Journal of Thrombosis and Haemostasis, 6(4), 632–637. https://doi.org/10.1111/j.1538-7836.2008.02911.x
Rogers, M. A., & Levine, D. A. (2018). Diagnosis and management of venous thromboembolism in pregnancy. Journal of Thrombosis and Thrombolysis, 45(2), 265–272. https://doi.org/10.1007/s11239-018-1629-2
Touloumakov, E. V., & Smirnov, V. V. (2020). Thromboprophylaxis in pregnancy: A review of guidelines. Journal of Perinatal Medicine, 48(8), 765–775. https://doi.org/10.1515/jpm-2020-0165
